How do you determine which systemic therapy to recommend in the 2nd line setting for metastatic, PD-L1 NEGATIVE cervical cancer?
Answer from: at Academic Institution
This is a very difficult situation because none of the available options are effective. Clinical trial or possibly pembrolizumab on compassion-care usage.
Comments
Medical Oncologist at Texas Oncology-San Antonio Babcock clinical trial with second or third generation IO.
clinical trial with second or third generation IO.